James Mulé
Academic Editor

James J. Mulé


Summary

- Executive Vice President and Associate Center Director for Translational Research
- Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment
- Co-Director of the Donald A. Adam Comprehensive Melanoma Research Center at the Moffitt Cancer Center.

Dr. Mulé is recognized for his research and clinical contributions to cancer immunotherapy, particularly in solid tumors. He has published nearly 200 articles in the areas of cancer vaccines and cancer immunotherapy; and he has been an NCI-NIH investigator continuously for nearly 20 years.

Dr. Mulé serves on the advisory board of M2Gen, a wholly-owned subsidiary of the Moffitt Cancer Center in the area of personalized medicine in oncology, which he helped to establish; the Board of Directors of Medicine in Need, Cambridge, MA (a non-profit spin-out of Harvard University, and selected as a 2011 Technology Pioneer by the World Economic Forum); and the advisory boards of several NCI-designated Cancer Centers and was a member of the NCI Director’s Board of Scientific Counselors (BSC-A, clinical), remaining a long-standing special government employee to the FDA and the NCI; the scientific/medical advisory boards of several private and public companies where he also served as a consultant; and he chaired the FDA’s CBER Cellular, Tissue, and Gene Therapy Advisory Committee.

Immunology Oncology Translational Medicine

Work details

Executive Vice President and Associate Center Director for Translational Research

H. Lee Moffitt Comprehensive Cancer Center
Departments of Immunology and Cutaneous Oncology
The clinical application of immunotherapy for cancer is rapidly moving forward in multiple areas, which incorporate the adoptive transfer of antitumor-reactive T cells and the use of 'therapeutic' vaccines. Both clinical and immunologic endpoints have shown new promise to the field. Novel dendritic cell-based vaccine strategies designed in the laboratory and proven in preclinical animal tumor models are now entering the clinic, with the intent of providing therapeutic efficacy. Improvements on this approach involve breaking tolerance to tumor 'self' antigens by inhibiting regulatory cells, boosting T cell co-stimulation, and administering combinations of recombinant cytokines and other defined molecules with 'immuno-enhancing' activities. Development of these improvements is the primary research interest of Dr. Mulé.

PeerJ Contributions